Exosens Stock Advances Mid-Day as Two Firms Upgrade Their Outlooks
Exosens stock progresses by 3.58% this Tuesday, February 3, 2026, in mid-session trading, priced at 54.90 euros. The stock continues its upward trend with a weekly performance of 2.81%. This development occurs in a context of favorable course target revisions by several analysts.
Stifel has significantly raised its course target on the light amplification technology specialist from 47 to 60 euros this February 3, while maintaining a 'buy' recommendation. This new target implies an appreciation potential of about 9% relative to the current stock level. Earlier, Bernstein had already increased its target to 71 euros on January 19, accompanied by an 'outperform' rating. This target suggests a potential upside of nearly 29% from the prices observed during the session. These successive adjustments reflect a strengthened confidence from the financial community in the company's prospects, as the stock has soared by 139.9% over the past year and 12.38% over the last quarter.
Technical Indicators Highlight Bullish Momentum
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The recent crossing of the 50-session moving average, established at 49.50 euros, underlines the strength of the ongoing bullish movement for Exosens. The stock is now trading above this key threshold, a signal generally interpreted as a favorable medium-term trend indicator. The RSI stands at 37, indicating a neutral technical situation that suggests neither overbought nor oversold conditions. This moderation in momentum indicators contrasts with the high monthly volatility of 9.70% and suggests room for further developments. The next resistance level is identified at 58.30 euros, while technical support remains identified around 45.35 euros. The beta of 0.14 further confirms the stock's low sensitivity to overall market fluctuations.
Nous sommes fiers de présenter notre performance sur les neuf premiers mois de l’année 2025, qui témoignent d'une croissance soutenue du chiffre d'affaires et de la marge brute ajustée, portée par la forte dynamique du secteur de la Défense.
Marché de la Défense très dynamique, forte demande pour la vision nocturne et les systèmes pour drones/anti-drones, croissance soutenue en Europe avec contribution des États-Unis et de l’Asie-Pacifique. Lancement commercial réussi des tubes 5G (plus de 5 000 commandes avant lancement).
Risks mentioned
Cession de l’activité Amplification par Micro-ondes entraînant une perte comptable sans impact de trésorerie en 2025
Dépendance aux budgets de Défense et aux évolutions géopolitiques
Risque d'intégration des acquisitions récentes
Incertitudes de la demande dans les Sciences de la Vie (marché américain)
Opportunities identified
Croissance adressable liée à la vision nocturne et aux applications drones/anti-drones
Commercialisation des tubes 5G avec commandes significatives (>5 000 tubes)
Expansion des capacités de production (+40% d’ici 2027) soutenant le développement commercial
Effets de croissance externe (Noxant, NVLS, Phasics) élargissant le marché adressable
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
